Taylor, William R.
Fedorka, Sara R.
Gad, Ibtissam
Shah, Ronit
Alqahtani, Hanan D.
Koranne, Radhika
Kuganesan, Nishanth
Dlamini, Samkeliso
Rogers, Tim
Al-Hamashi, Ayad
Kholodovych, Veronika
Barudi, Yusuf
Junk, Damian
Rashid, Maisha S.
Jackson, Mark W.
Tillekeratne, L. M. Viranga
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R15GM100440, GM120712)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA213185, CA213185, R15CA213185)
Article History
Received: 7 June 2018
Accepted: 22 March 2019
First Online: 11 April 2019
Competing Interests
: L.M.V.T., S.R.F. and W.R.T. are co-inventors of patents (US9862692B2 and US10138216B2) that covers these anticancer agents. The authors declare no other financial or non-financial interests.